

# Clearance of von Willebrand factor

Cécile V. Denis<sup>1</sup>, Olivier D. Christophe<sup>1</sup>, Beatrjjs D. Oortwijn<sup>2</sup>, Peter J. Lenting<sup>2,3</sup>

<sup>1</sup>INSERM U770, Le Kremlin-Bicêtre, France; Univ. Paris-Sud, Le Kremlin-Bicêtre, France; <sup>2</sup>Laboratory for Thrombosis and Haemostasis, Department of Clinical Chemistry & Haematology, University Medical Center Utrecht, Utrecht, the Netherlands; <sup>3</sup>Crucell Holland B.V., Department of Protein Discovery, Leiden, the Netherlands

## Summary

The life cycle of von Willebrand factor (VWF) comprises a number of distinct steps, ranging from the controlled expression of the VWF gene in endothelial cells and megakaryocytes to the removal of VWF from the circulation. The various aspects of VWF clearance have been the objects of intense research in the last few years, stimulated by observations that VWF clearance is a relatively common component of the pathogenesis of type I von Willebrand disease (VWD). Moreover, improving the survival of VWF is now considered as a viable therapeutic strategy to prolong the half-life of factor VIII in order to optimise treatment of haemophilia A. The present review aims to provide an

overview of recent findings with regard to the molecular basis of VWF clearance. A number of parameters have been identified that influence VWF clearance, including its glycosylation profile and a number of VWF missense mutations. In addition, in-vivo studies have been used to identify cells that contribute to the catabolism of VWF, providing a starting point for the identification of receptors that mediate the cellular uptake of VWF. Finally, we discuss recent data describing chemical modification of VWF as an approach to prolong the half-life of the VWF/FVIII complex.

## Keywords

Von Willebrand factor, factor VIII, animal models, von Willebrand disease

Thromb Haemost 2008; 99: 271–278

## Introduction

For each organism, the regulation of protein levels is a key process that requires a delicate balance between biosynthesis and elimination. Defects in clearance mechanisms may result in deficiency or an accumulation of certain components, which may eventually provoke pathological manifestations. For instance, the accumulation of amyloid  $\beta$  peptide due to reduced LRP-mediated clearance contributes to the pathogenesis of Alzheimer disease (1, 2), whereas defects in the clearance of lipoprotein particles are associated with familial hypercholesterolemia (3). These two examples illustrate the universal requirement for mechanisms that control the clearance of proteins, and the haemostatic system is not an exception in this regard.

One important player of the haemostatic system is von Willebrand factor (VWF). VWF is a multimeric protein which contributes to the initial recruitment of platelets to injured vessel by acting as a molecular bridge between the exposed subendothelial matrix and the platelet receptors GpIb/IX/V and  $\alpha$ IIB $\beta$ 3 (4). Apart from its role in primary haemostasis, a number of other

functions have been recognized as well. First, VWF and its pro-peptide are indispensable for the intracellular formation of endothelial-specific storage organelles, the Weibel-Palade bodies (5, 6). These organelles are not only a storage-compartment for ultra-large VWF multimers, but also for a variety of other proteins, such as P-selectin, interleukin-8 and angiopoietin-2 (for reviews see [7, 8]). Second, the presence of VWF has a suppressing effect on the metastatic potential of tumour cells (9). Third, VWF comprises binding sites for *Staphylococcal aureus*-surface proteins (protein A), which may facilitate intravascular colonisation by these pathogens (10–12). Further, VWF may promote the proliferation of smooth muscle cells (13). Finally, we have recently reported on the ability of VWF to act as an adhesive surface for leukocytes (14). VWF-leukocyte interactions involve P-selectin glycoprotein ligand 1 (PSGL-1) as well as the family of  $\beta$ 2-integrins.

Another intriguing aspect of VWF is that it functions as a carrier to transport other proteins in the circulation. A recent example of a molecule that uses VWF as a molecular vehicle is osteoprotegerin. This protein is co-expressed with VWF in en-

Correspondence to:

Dr. C.V. Denis  
INSERM U770  
80 rue du Général Leclerc  
94276 Le Kremlin-Bicêtre Cedex, France  
Tel.: +33 | 49 59 56 05, Fax: +33 | 46 71 94 72  
E-mail: denis@kb.inserm.fr

Received October 22, 2007  
Accepted after minor revision December 11, 2007

Republished online January 11, 2008  
doi:10.1160/TH07-10-0629

endothelial cells, and upon secretion both proteins remain in complex (15, 16). The physiological relevance of complex formation between VWF and osteoprotegerin is yet unknown and remains to be resolved. The necessity for complex formation with VWF is much clearer for coagulation factor VIII (FVIII). FVIII is a plasma protein that functions as a cofactor for activated factor IX, and functional deficiency of FVIII leads to impaired generation of activated factor X (17). This deficiency is associated with a severe bleeding tendency, known as haemophilia A (18). Patients lacking VWF are characterized by a secondary deficiency of FVIII (19), demonstrating that VWF is essential for appropriate survival of FVIII.

The present review aims to summarize recent developments regarding clearance of VWF. Knowledge of the mechanisms that are responsible for the clearance of VWF complex is important, because modulated clearance of VWF has been found to contribute to the pathogenesis of certain forms of von Willebrand disease (VWD). Moreover, since VWF is critical for the survival of FVIII, manipulating VWF clearance may be an approach to improve survival of FVIII in order to reduce the treatment-frequency of haemophilia A patients.

## Biosynthesis of VWF

VWF is produced in endothelial cells and megakaryocytes (20, 21). Megakaryocytic production is responsible for the presence of VWF in the  $\alpha$ -granules of platelets, whereas endothelial cells are the primary source of VWF that is found in the subendothelial matrix and in plasma. Biosynthesis generates a single-chain pre-pro-polypeptide of 2813 amino acids, in which a number of domain structures can be distinguished: D1-D2-D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK (19). After removal of the signal peptide, pro-VWF subunits undergo tail-to-tail linkage via disulphide bonding within the cysteine-rich CK-domains, resulting in pro-VWF dimers. Further processing proceeds within the Golgi apparatus and involves multimerization via intramolecular cysteine-bonding within the D'-D3 domains. This process produces a heterogeneous pool of differentially sized multimers, with molecular masses ranging from  $0.5 \times 10^6$  to over  $10 \times 10^6$  Da. Imperative to this multimerization is binding of propeptide (D1-D2 domains) to the D'-D3 region, an interaction which is optimal under slightly acidic conditions such as those present in the Golgi apparatus (20, 22). Indeed, defective interactions between propeptide and D'-D3 domains lead to impaired multimerization (23). Of interest, the slightly acidic conditions needed for optimal propeptide binding also apply to the binding of proteins that co-localize with VWF in the endothelial storage organelles, such as osteoprotegerin and IL-8 (16, 24).

Finally, limited proteolysis in the trans-Golgi network separates the propeptide from the mature VWF multimer. Proteolysis is believed to be mediated by furin, which recognizes a positively-charged sequence downstream the Arg763-Ser764 cleavage site (25). Mutations in this area lead to incomplete removal of the propeptide, thereby generating pro-VWF multimers displaying suboptimal FVIII binding (26, 27). Following proteolysis, VWF is targeted to the storage organelles. Noteworthy, both VWF and propeptide are absolutely necessary for Weibel-Palade body formation, whereas  $\alpha$ -granule formation occurs in their ab-

sence. Endothelial cells obtained from animals with a complete VWF-deficiency indeed lack Weibel-Palade bodies (5, 28), and the formation of these storage-organelles can be restored upon transfection with VWF (5). The importance of VWF for Weibel-Palade body formation is further underscored by the fact that mutations associated with impaired multimerization also affect size and number of Weibel-Palade bodies (7).

## Glycosylation of VWF

Apart from multimerization and proteolytic processing, VWF is also subject to extensive glycosylation. The amino acid sequence of VWF predicts the site of 12 *N*-linked and 10 *O*-linked oligosaccharide side-chains, and this extensive number of glycans contributes to almost 20% of the molecular mass of the VWF molecule (29). *N*-linked glycosylation is initiated within the endoplasmic reticulum, and this process continues within the Golgi apparatus. *N*-linked glycans on VWF display a wide spectrum of complexity, and include bi- tri- and tetra-antennary structures (30). Interestingly, VWF is one of the few plasma proteins that have blood group A, B and H antigenic structures incorporated in their oligosaccharide side-chains (31). It is important to stress that the blood group determinants are attached to the *N*-linked but not the *O*-linked structures (32). As for the *O*-linked glycans, the majority consists of sialylated T-antigen, a mucin-type core 1 structure (32). The contribution of glycosylation to VWF biology is still a poorly understood area, despite many years of research. It seems conceivable to assume that optimal glycosylation is required for proper synthesis and secretion. Furthermore, the presence of the glycan structures also seems to be involved in regulating VWF function, an issue that is discussed in more detail elsewhere (33, 34). Finally, the glycosylation profile of VWF has proven to be a prominent parameter that influences VWF plasma levels.

## Glycosylation of VWF: Effect of blood group determinants on VWF levels

More than two decades ago, it was already recognized that VWF levels are lower in individuals having blood group O compared to those having non-O (35), and this observation has been confirmed in many other studies (reviewed in [34]). On average, VWF concentrations are approximately 25% lower in persons with blood group O than those in non-O individuals. Levels are even more reduced in persons with the Bombay-phenotype, who lack expression of ABO-antigens (36).

How to explain the lower levels of VWF in those who have blood group O? Studies by O'Donnell et al. have provided evidence that the effect is mediated by the ABH antigenic structures present on the VWF molecule self rather than via indirect mechanisms (37). They found a correlation between expression levels of A-transferase, the amount of A antigenic determinants present on the VWF molecule and corresponding VWF levels. A similar relationship between the loading of VWF with A or B determinants and VWF levels has more recently been reported by Morelli et al. (38). Thus, in some way the blood group determi-

nants present on the VWF molecule affect biosynthesis, secretion, clearance or a combination thereof.

Attempts to address the effect of blood group determinants on biosynthesis and secretion *in vitro* have been proven to be difficult, because of the absence of A- and B-transferase activity in isolated human umbilical vein endothelial cells, the main primary cell type that is used to study VWF biology (39, 40). However, a number of arguments are available that point against a major effect of the blood group determinants on biosynthesis and/or secretion. First, VWF concentrations in platelets are affected to a minor extent by blood group type (41), indicating that the blood group determinants do not affect synthesis and storage in megakaryocytes. Second, the rise in VWF levels upon desmopressin treatment appears to be similar for patients with different blood groups (42), suggesting similar efficiency of VWF secretion from endothelial storage pools.

Based on these observations, it seems conceivable that the effect of blood group determinants is most likely affecting clearance of VWF. Although not formally proven, there are a number of observations that are in support of this possibility. First, preliminary data were recently presented concerning the half-life of VWF following desmopressin treatment in healthy individuals (43). It was found that the half-lives were significantly shorter in O-subjects than in non-O-subjects. Another observation relates to the ratio between VWF propeptide and mature VWF. VWF propeptide and mature VWF are released simultaneously in a 1:1 molar ratio. However, propeptide is cleared three- to four-fold more rapidly than VWF, resulting in distinct propeptide/VWF ratio under steady-state conditions (44). Interestingly, this ratio is dissimilar between individuals with different blood groups, in that blood group O individuals have an increased ratio compared to non-O persons (45, 46). Given the notions that i) VWF and propeptide are released in a 1:1 ratio and ii) propeptide levels are unaffected by blood group, it should follow that VWF has a shorter half-life in blood group O persons. This possibility has been addressed by Nossent et al. using a model assuming that the propeptide half-life is more or less constant amongst individuals. This model predicts the half-life of endogenous VWF to be two hours (h) longer in non-O persons compared to blood group O persons (46). Finally, several studies have reported that the half-life of infused FVIII correlates with steady-state VWF levels, its carrier protein (47, 48). When we analysed this correlation in a cohort of 38 haemophilia A patients, we found that this correlation is strongly influenced by blood group (Fig. 1). This may explain that why the half-life of FVIII (irrespective whether it is recombinant or plasma-derived), is considerably shorter in haemophilia A patients with blood group O with FVIII half-lives being  $11.5 \pm 2.6$  h and  $14.3 \pm 3.0$  h ( $p = 0.0044$ ) in O- and non-O patients, respectively. A similar effect of blood group on FVIII survival has previously been reported (48). Since no blood group determinants are present on the FVIII molecule, the most logical explanation for the blood-group-dependent half-life of FVIII is that the half-life of its carrier protein VWF is determined by the blood group determinants.


The notion that ABO-determinants influence VWF clearance may be of relevance for the development of VWF preparations for therapeutic use, for instance by increasing the amounts of

non-O VWF molecules in plasma-derived VWF concentrates. Moreover, in view of the development of a recombinant-derived VWF therapeutic preparation (49), it is of importance to investigate how the non-human glycosylation profile affects the survival of VWF in humans. In particular, it is of relevance to exclude that the glycan profile of recombinant VWF mimics that of the Bombay-phenotype, since this phenotype is associated with low VWF levels (36).

Apart from the ABO-blood group effect, other blood group-dependent modifications of the glycosylation profile may also affect VWF plasma levels. An example hereof is the *Secretor* system, which is involved in the ability to secrete blood type antigens in body fluids. Persons with blood group O and the *SeSe*-genotype have significantly higher VWF levels (approximately 20%) compared to those with the O-blood group combined with the *Sese*- or *sese*-genotype (50). It is not known whether secretor-dependent modifications affect VWF clearance, and propeptide-analysis would provide insight in this regard.

### The effect of glycosylation on VWF clearance: Sialylation

As for most human glycoproteins, also oligosaccharides side-chains on VWF contain terminal sialyl-residues. For many proteins it has been demonstrated that sialyl-groups covering galactose-residues are needed to prevent premature clearance of these proteins by carbohydrate-recognizing receptors, such as asialoglycoprotein-receptor. Enzymatic removal of sialyl-resi-



**Figure 1: Association between pre-infusion VWF levels and FVIII half-life depends on blood group.** FVIII half-life was determined in a cohort of 38 severe haemophilia A patients (85) and observed half-lives are plotted versus pre-infusion VWF levels. In agreement with previous studies (see [47, 48]), a statistically significant correlation between FVIII half-life and VWF antigen levels is observed ( $p = 0.001$ ). Surprisingly, this correlation appeared to be different for patients having blood group O (open circles;  $n=19$ ) or blood group non-O (closed circles;  $n=19$ ). These data further show that average half-life of FVIII is shorter in haemophilia A patients having blood group O ( $11.5 \pm 2.6$  h) compared to patients having blood group non-O ( $14.3 \pm 3.0$  h).

duces from VWF results in molecules that have a markedly short half-life when injected in rabbits (240 and 5 minutes for normal and de-sialylated VWF, respectively) (51), suggesting that sialyl-groups are also needed to protect VWF from premature clearance. The physiological relevance of VWF sialylation has elegantly been demonstrated by Ellies et al., who reported that in a patient group referred to the hospital for real or suspected bleeding disorder, reduced sialylation by sialyl-transferase ST3Gal-IV was associated with reduced VWF plasma levels (52). Also in a more recent study by Millar et al., the half-life of VWF released upon desmopressin was found to correlate with the extent of sialylation (53). Furthermore, the half-life of endogenous VWF was reduced by two-fold in mice lacking sialyl-transferase ST3Gal-IV, which display impaired sialylation (52).

The value of animal models to investigate the relationship between glycosylation and regulation of VWF levels, is most vividly illustrated by the work of Ginsburg et al. using the RIIS/J mouse strain. This mouse strain is characterized by VWF levels that are several-fold lower compared to other mouse strains (54). Via a crossbreeding approach, it was demonstrated that the gene responsible for these low VWF levels was distinct from the VWF gene (55). More detailed studies identified this VWF-modifier gene as being *Galgt2* (currently renamed as *B4galnt2*), which encodes a *N*-acetylgalactosaminyltransferase (56). The activity of this enzyme determines the expression of an oligosaccharide specific for a murine T cell subpopulation (57). The human equivalent of this enzyme is responsible for expression of the blood-group antigen Sd<sup>a</sup>. Murine expression of this glycosyl-transferase is normally limited to intestine and kidney. In RIIS/J

mice, a genetic defect relieves this restriction and endows endothelial expression, allowing it to enrich VWF with a surplus of terminal *N*-acetylgalactosamine residues (58). Upon secretion into plasma, this form of VWF is readily recognized by the asialoglycoprotein-receptor and subject to rapid clearance.


Both the ST3Gal-IV-deficient and RIIS/J mouse models have provided important insight into the interplay between VWF glycosylation and survival, and it leaves no doubt that in the future more relevant information will be revealed using similar approaches.

## The effect of glycosylation on VWF clearance: O-linked glycosylation

The complexity of VWF glycosylation is underscored by the presence of both *N*- and *O*-linked glycans. Whereas the *N*-linked side-chains are more or less evenly dispersed over the molecule, the *O*-linked glycans are mainly clustered around the platelet-binding A1 domain. It is not surprising therefore that several studies have demonstrated the regulatory role of *O*-linked glycans in VWF-platelet interactions (59, 60). As for their role in regulating VWF clearance, initial studies revealed that suppression of *O*-linked glycosylation during synthesis gave rise to recombinant VWF preparations with a strongly reduced half-life in rats (61). This may indicate that the presence of *O*-linked glycans protects VWF from rapid clearance, either via prevention of VWF-binding to clearance receptors or by avoiding improper folding of VWF.

The majority of the *O*-linked glycans consist of the sialylated tumor-associated T-antigen (32). This structure consists of the disaccharide galactose-( $\beta$ 1-3)-*N*-acetylgalactosamine and is sialylated through capping with two *N*-acetylneuramic acid residues (i.e. NeuAc( $\alpha$ 2-3)Gal-( $\beta$ 1-3)-[NeuAc( $\alpha$ 2-6)]GalNAc). Previously, it has been shown that this glycan structure on VWF can be detected using peanut agglutinin-lectin, but only after removal of sialyl-residues (62). We used this lectin to quantify loading of VWF with *O*-linked glycans. Unexpectedly, there appeared to be an inverted relationship between loading with *O*-glycans and VWF levels in a cohort of over 100 healthy subjects; thus the more glycosylation, the lower the levels of VWF (63). Also in cohorts of patients having either unusually high or unusually low levels of VWF, this correlation was observed (Fig. 2). For instance, liver cirrhosis patients have levels of VWF that may be increased up to 20-fold of normal. In these patients, the extent of *O*-linked sialylated T-antigen was significantly reduced by more than two-fold on average, and near undetectable in some of them. In contrast, increased loading with *O*-linked glycans (up to 4-fold) was observed in patients with reduced levels of VWF and classified as VWD-type 1.

It remains to be investigated whether or not *O*-linked glycans affect VWF levels by modulating clearance of the protein. It should be noted that we found a linear correlation between loading with *O*-linked glycans and propeptide/VWF ratios in VWD-type 1 patients. Since this ratio may be considered a surrogate marker for clearance, it seems that *O*-linked glycans may indeed contribute to the in-vivo survival of VWF. Further studies are needed to investigate whether manipulation of *O*-linked glyco-



**Figure 2: Correlation between extent of glycosylation with sialylated T-antigen (represented by PNA-binding) versus VWF antigen levels.** From different cohorts plasma samples were analysed for the presence of sialylated T-antigen using the biotinylated peanut agglutinin-lectin (for details on assay see [63]). Cohorts included von Willebrand disease-type 1 patients (VWD patients) and their unaffected family members (unaffected FM), patients with liver cirrhosis (Cirrhosis patients) and healthy controls. It appears that the extent of sialylated T-antigen loading inversely correlates with VWF levels in a non-linear manner (please note the log-scale for VWF levels).

sylation may be used to alter the half-life of recombinant VWF molecules.

## The effect of proteolysis on VWF clearance

VWF circulates as a heterologous set of differently sized molecules. Apart from the intact multimeric proteins, it has been recognized that also proteolytic fragments of VWF are present in plasma (64). Proteolysis occurs within the A2-domain between residues Tyr1605 and Met1606, and is mediated by a VWF-specific protease from the ADAMTS-family (*A Disintegrin and Metalloprotease with Thrombospondin motif*), i.e. ADAMTS13 (65, 66). It is not uncommon that proteolysis of proteins is taken by the body as a sign for removal, and it has been suggested that this may apply to VWF as well (67). However, the available data are not in support of this hypothesis. First, no difference in survival was observed for intact VWF and proteolysed fragments that were present in plasma-derived VWF preparations, which we infused in VWF-deficient mice (Lenting and Denis, unpublished observations). Second, Stoddart et al. compared the survival of wild-type VWF and a proteolysis-sensitive VWF mutant in rats, and could not detect differences in survival of both proteins (61). In view of the low susceptibility of human VWF for proteolysis by murine ADAMTS13, it cannot be excluded that the observed similarity in clearance in the study by Stoddart originates from a low proteolytic activity of rat ADAMTS13 towards human VWF. To avoid potential complications caused by species-differences, we analysed steady-state VWF levels in ADAMTS13-deficient mice and their wild-type littermates, assuming that levels should be higher in ADAMTS13-deficient mice if proteolysis enhances clearance. However, no differences in VWF levels could be detected in this regard (Lenting and Denis, unpublished observations). The relationship between ADAMTS13 levels and VWF half-life has also been examined using patients with VWD-type 1 or haemophilia A (68). This study could not establish a correlation between ADAMTS13 levels and post-desmopressin survival of VWF, thereby providing further evidence against ADAMTS13 contributing to clearance of VWF. Whether other proteases exist which are able to modify VWF survival is yet unknown, but deserves further studies.

## Modified clearance in the pathogenesis of VWD

Inspection of the VWD database reveals a large number of missense mutations associated with qualitative (VWD-type 2 mutations) or quantitative (VWD-type 1 and type 3 mutations) consequences. In the previous decades, the effect of many mutations on synthesis and secretion of VWF has been studied, providing insight on why these mutations are associated with reduced VWF levels (19). It is only recent that it has been recognized that low levels of VWF in VWD patients may also originate from modified clearance (69). The first report on the association between increased clearance and VWD appeared in 2002, and described the rapid disappearance of VWF upon treatment with desmopressin in seven VWD patients carrying the combined M749I/R1205H mutations (26). Additional studies revealed that these patients were not unique with regard to decreased survival of VWF. Brown et al. demonstrated that the average survival of

VWF was shorter in a large group of VWD-type 1 patients than in haemophilia patients (42). It should be noted that a detailed evaluation of the individual patients was not provided in this report. Nevertheless, these data provide an important indication of the common occurrence of increased clearance in the pathogenesis of VWD type 1. More detailed analysis of the correlation between certain mutations in VWF and their effect on VWF clearance has been provided in a number of other studies. Van Schooten et al. described the increased clearance of VWF in patients harbouring selective cysteine-mutations (Cys1130Phe, Cys1149Arg, Cys2671Tyr), whereas Haberichter et al. reported decreased survival in families having either a Tyr1144Gly or a Ser2179Phe mutation (23, 45). Thus, six different mutations have currently been linked to abnormal VWF clearance, and it leaves no doubt that this spectrum of mutations will expand in the future.

It is important to realise that the above mentioned studies analyzed the survival of endogenous VWF following desmopressin treatment, making it difficult to distinguish between increased clearance being caused by the amino acid replacement, additional gene mutations or secondary defects in clearance receptors for VWF. In addition, the determination of the half-life is often based on a few time-points, which prevents accurate calculation of these half-lives. It is obligatory therefore, that additional studies are being performed in a more controlled environment. We have chosen to do so by addressing the survival of recombinant VWF mutants in VWF deficient mice (23, 70). This approach not only provides information regarding pharmacokinetic parameters of wild-type and mutant molecules, but also allows us to study their cellular targeting.

As for the translation to the clinical environment, insight into the survival aspects of VWF in VWD patients is of relevance concerning the way by which these patients are treated. If the half-life of endogenous VWF is too short, it might be preferential to apply replacement therapy rather than desmopressin treatment in these patients. The question is then: how to identify patients that have reduced VWF levels because of a reduced survival of their VWF? To perform extensive half-life studies might be a major burden for patients. We feel that relevant information can be derived from the propeptide/VWF ratios. Increased propeptide/VWF ratios have been found in patients with increased clearance (23, 45) and this ratio could therefore serve as a surrogate marker for increased clearance.

## Clearance receptors for VWF: An unexplored aspect of VWF biology

At present, no information is available about which cells and which receptors contribute to the removal of VWF from the circulation. In order to get such information, we used our VWF-deficient mouse model to identify tissues that are of importance for VWF clearance. Intravenous injection of VWF resulted in the accumulation of the bulk of VWF protein in the liver (70). However, VWF was also found in a number of other organs, like spleen and kidneys. Taking the size of each of these organs into account, VWF was taken up relatively efficiently by both liver and spleen in particular (71). We are currently trying to establish

which cells within these tissues are responsible for the cellular uptake for VWF. Preliminary immuno-histochemical analysis revealed considerable co-localisation between VWF and specific markers for macrophage cells, pointing to a role for macrophages in both liver and spleen as dominant cells that endocytose VWF (71). This observation is in line with an observation made by Sodetz et al., who reported that blockade of the reticuloendothelial system (which consists of phagocytotic cells, such as Kupffer cells) resulted in a delayed clearance of the VWF/FVIII complex (51).

The mechanism by which these cells take up VWF requires further investigation. The molecular size of multimeric VWF may span several hundred nanometres when in a coiled conformation (72). It is unlikely therefore that VWF is able to enter cells via the classical pathways involving clathrin-coated pits or caveolae, simply because of its physical dimensions. In this respect, our finding that macrophages are able to take up this relatively large molecule is in line with the capacity of these cells to rapidly endocytose large particles such as microbes. Whether or not this involves a receptor-mediated or receptor-independent process remains to be established. However, we have recently found that VWF may act as an adhesive surface for leukocytes by interacting with the leukocyte-specific  $\beta 2$ -integrin family. This family has been recognized as an important mediator involved in the uptake of bacteria and other pathogens by macrophages, and could therefore also serve as an endocytic receptor for VWF.

## VWF as a tool to prolong the half-life of FVIII

Current treatment of haemophilia A mainly involves replacement therapy using purified plasma-derived or recombinant FVIII preparations. Although part of the patients is still treated on an “on-demand”-basis, prophylactic treatment has become more common during the previous decade and often initiated after the occurrence of one or two joint bleeds. Although prophylactic treatment has resulted in a marked improvement of quality-of-life for haemophilia A patients, its application is still hampered by the requirement of frequent infusion (up to 3 times per week) because of the relatively short half-life of FVIII. In order to improve half-life of FVIII a number of initiatives have been taken. Most of the approaches are directly targeting the FVIII molecule, for instance via chemical conjugation of FVIII using polyethylene glycol polymers (i.e. PEGylation). For a number of other proteins, this approach has been shown to encompass a powerful tool to increase half-life. Preliminary data describing the analysis of PEGylated FVIII in mice show that direct PEGylation of FVIII indeed is associated with an increased half-life (73). However, it also appeared that PEGylation of FVIII may result in loss of at least part of its activity, thereby

requiring higher doses for infusion (74).

Given the observation that half-life of FVIII is strongly influenced by VWF, it is of interest to consider VWF as a target to indirectly modulate FVIII half-life. In the circulation, the majority of the FVIII molecules (95–98%) are in complex with VWF (75, 76). In view of the high affinity of the complex (the affinity constant is less than 1 nM [77, 78]), it seems reasonable to assume that VWF-bound FVIII follows VWF in its clearance pathway. This possibility has been explored by Turecek et al., who reported that modification of VWF via polysialylation or PEGylation gave rise to VWF molecules that displayed increased half-life when tested in VWF-deficient mice (79, 80). Moreover, the prolonged half-life of PEGylated VWF was associated with an increased survival of FVIII which was co-injected with the conjugated VWF molecules. It should be noted that the increase in FVIII half-life was less pronounced than the prolongation for VWF, probably because free FVIII that dissociates from the complex is susceptible to rapid clearance via for instance LDL-receptor related protein-1 (69). Furthermore, the binding capacity of PEGylated VWF to bind FVIII appeared to be reduced, although the affinity of the complex remained unchanged.

One final consideration in this regard relates to the potential side-effects of chemically modifying either FVIII or VWF. Several studies have shown that PEGylated proteins often exhibit reduced immunogenicity *in vivo* (81, 82). It has been suggested that PEGylation-dependent reduction of immunogenicity may also apply to FVIII (83). However, it is also of importance to mention that PEGylation of protein may increase immunogenicity, as became apparent during clinical trials using a PEGylated recombinant fragment of human thrombopoietin (i.e. PEG-rHuMGDF). The development of inhibitory antibodies against this PEGylated molecule forced the termination of these clinical trials (84).

## Conclusion

Taken together, we feel that exciting new data have been generated in the last few years with regard to the clearance of VWF. These data constitute the prelude for a better understanding of the apparently complex catabolic pathway of this intriguing molecule. Elucidating the molecular basis of VWF clearance is of importance to explore new avenues to improve treatment of VWD and haemophilia A.

## Acknowledgements

We would like to thank Dr. H. M. van den Berg and Dr. C. J. van Schooten for their valuable contributions during our studies. Part of our studies has been supported by a Bayer Haemophilia Award.

## References

1. Zlokovic BV. Clearing amyloid through the blood-brain barrier. *J Neurochem* 2004; 89: 807–811.
2. Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. *Nat Med* 2007; 13: 1029–1031.
3. Pullinger CR, Kane JP, Malloy MJ. Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders. *Expert Rev Cardiovasc Ther* 2003; 1: 107–119.
4. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. *J Thromb Haemost* 2003; 1: 1335–1342.
5. Haberichter SL, Merricks EP, Fahs SA, et al. Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. *Blood* 2005; 105: 145–152.
6. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. *Blood* 1994; 83: 3536–3544.

7. Michaux G, Cutler DF. How to roll an endothelial cigar: the biogenesis of Weibel-Palade bodies. *Traffic* 2004; 5: 69–78.
8. Rondajli MG, Bierings R, Kragt A, et al. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. *Arterioscler Thromb Vasc Biol* 2006; 26: 1002–1007.
9. Terraube V, Pendu R, Baruch D, et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. *J Thromb Haemost* 2006; 4: 519–526.
10. O'Seaghda M, van Schooten CJ, Kerrigan SW, et al. Staphylococcus aureus protein A binding to von Willebrand factor A1 domain is mediated by conserved IgG binding regions. *FEBS J* 2006; 273: 4831–4841.
11. Pawar P, Shin PK, Mousa SA, et al. Fluid shear regulates the kinetics and receptor specificity of Staphylococcus aureus binding to activated platelets. *J Immunol* 2004; 173: 1258–1265.
12. Hartleib J, Kohler N, Dickinson RB, et al. Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. *Blood* 2000; 96: 2149–2156.
13. Qin F, Impeduglia T, Schaffer P, et al. Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: preliminary studies. *J Vasc Surg* 2003; 37: 433–439.
14. Pendu R, Terraube V, Christophe OD, et al. P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. *Blood* 2006; 108: 3746–3752.
15. Zannettino AC, Holding CA, Diamond P, et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. *J Cell Physiol* 2005; 204: 714–723.
16. Shahbazi S, Lenting PJ, Fribourg C, et al. Characterization of the interaction between von Willebrand factor and osteoprotegerin. *J Thromb Haemost* 2007; 5: 1956–1962.
17. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. *Blood* 1998; 92: 3983–3996.
18. Graw J, Brackmann HH, Oldenburg J, et al. Haemophilia A: from mutation analysis to new therapies. *Nat Rev Genet* 2005; 6: 488–501.
19. Sadler JE. Biochemistry and genetics of von Willebrand factor. *Annu Rev Biochem* 1998; 67: 395–424.
20. Wagner DD. Cell biology of von Willebrand factor. *Annu Rev Cell Biol* 1990; 6: 217–246.
21. Piovello F, Ascari E, Sitar GM, et al. Immunofluorescent detection of factor VIII-related antigen in human platelets and megakaryocytes. *Haemostasis* 1974; 3: 288–295.
22. Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. *J Cell Biol* 1986; 102: 1320–1324.
23. van Schooten CJ, Tjernberg P, Westein E, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. *J Thromb Haemost* 2005; 3: 2228–2237.
24. Bierings R, van den Biggelaar M, Kragt A, et al. Efficiency of von Willebrand factor-mediated targeting of IL-8 into Weibel-Palade bodies. *J Thromb Haemost* 2007; 5: 2512–2519.
25. van de Ven WJ, Voorberg J, Fontijn R, et al. Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes. *Mol Biol Rep* 1990; 14: 265–275.
26. Casonato A, Pontara E, Sartorello F, et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. *Blood* 2002; 99: 180–184.
27. Hilbert L, Nurden P, Caron C, et al. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide. *Thromb Haemost* 2006; 96: 290–294.
28. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. *Proc Natl Acad Sci USA* 1998; 95: 9524–9529.
29. Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. *Biochemistry* 1986; 25: 3171–3184.
30. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. *J Biol Chem* 1992; 267: 8723–8731.
31. Sodetz JM, Paulson JC, McKee PA. Carbohydrate composition and identification of blood group A, B, and H oligosaccharide structures on human Factor VIII/von Willebrand factor. *J Biol Chem* 1979; 254: 10754–10760.
32. Samor B, Michalski JC, Mazurier C, et al. Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor. *Glycoconj J* 1989; 6: 263–270.
33. Millar CM, Brown SA. Oligosaccharide structures of von Willebrand factor and their potential role in von Willebrand disease. *Blood Rev* 2006; 20: 83–92.
34. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? *Transfusion* 2006; 46: 1836–1844.
35. McCallum CJ, Peake IR, Newcombe RG, Bloom AL. Factor VIII levels and blood group antigens. *Thromb Haemost* 1983; 50: 757.
36. O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. *Blood* 2005; 106: 1988–1991.
37. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. *Arterioscler Thromb Vasc Biol* 2002; 22: 335–341.
38. Morelli VM, de Visser MC, Van Tilburg NH, et al. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. *Thromb Haemost* 2007; 97: 534–541.
39. O'Donnell J, Mille-Baker B, Laffan M. Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens. *J Vasc Res* 2000; 37: 540–547.
40. O'Donnell J, Laffan MA. Dissociation of ABH antigen expression from von Willebrand factor synthesis in endothelial cell lines. *Br J Haematol* 2003; 121: 928–931.
41. Sweeney JD, Hoernig LA. Intraplatelet von Willebrand factor and ABO blood group. *Thromb Res* 1992; 68: 393–398.
42. Brown SA, Eldridge A, Collins PW, et al. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? *J Thromb Haemost* 2003; 1: 1714–1717.
43. Gallinaro L, Cattini MG, Bertomoro A, et al. How ABO blood groups affect von Willebrand factor levels in normal subjects. *J Thromb Haemost* 2007; 5 (Suppl 1): P-T-200.
44. Borchellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. *Blood* 1996; 88: 2951–2958.
45. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. *Blood* 2006; 108: 3344–3351.
46. Nossent AY, Van Marion V, Van Tilburg NH, et al. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. *J Thromb Haemost* 2006; 4: 2556–2562.
47. Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. *Br J Haematol* 1995; 91: 474–476.
48. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, et al. The half-life of infused factor VIII is shorter in hemophilic patients with blood group O than in those with blood group A. *Thromb Haemost* 2000; 83: 65–69.
49. Plaimauer B, Schlokot U, Turecek PL, et al. Recombinant von Willebrand factor: preclinical development. *Semin Thromb Hemost* 2001; 27: 395–403.
50. O'Donnell J, Boulton FE, Manning RA, et al. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. *Br J Haematol* 2002; 116: 350–356.
51. Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. *J Biol Chem* 1977; 252: 5538–5546.
52. Ellies LG, Ditto D, Levy GG, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. *Proc Natl Acad Sci USA* 2002; 99: 10042–10047.
53. Millar CM, Riddel AF, Brown SA. Quantitation of Binding of Ricinus communis Agglutinin I to Von Willebrand Factor (VWF): Investigation of Relationship with Plasma Clearance of VWF in Type 1 Von Willebrand Disease. *ASH Annual Meeting Abstracts* 2005; 106: 727.
54. Sweeney JD, Novak EK, Reddington M, Takeuchi KH, Swank RT. The RIIS/J inbred mouse strain as a model for von Willebrand disease. *Blood* 1990; 76: 2258–2265.
55. Mohlke KL, Nichols WC, Westrick RJ, et al. A novel modifier gene for plasma von Willebrand factor level maps to distal mouse chromosome 11. *Proc Natl Acad Sci USA* 1996; 93: 15352–15357.
56. Morange PE, Tregouet DA, Frere C, et al. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. *Br J Haematol* 2005; 128: 91–99.
57. Smith PL, Lowe JB. Molecular cloning of a murine N-acetylgalactosamine transferase cDNA that determines expression of the T lymphocyte-specific CT oligosaccharide differentiation antigen. *J Biol Chem* 1994; 269: 15162–15171.
58. Mohlke KL, Purkayastha AA, Westrick RJ, et al. Mvfw, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. *Cell* 1999; 96: 111–120.
59. Carew JA, Quinn SM, Stoddart JH, Lynch DC. O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein Ib. *J Clin Invest* 1992; 90: 2258–2267.
60. Schulte am Esch J, Robson SC, Knoefel WT, et al. Impact of O-linked glycosylation of the VWF-A1-domain flanking regions on platelet interaction. *Br J Haematol* 2005; 128: 82–90.
61. Stoddart JH, Jr., Andersen J, Lynch DC. Clearance of normal and type 2A von Willebrand factor in the rat. *Blood* 1996; 88: 1692–1699.
62. Matsui T, Hamako J, Ozeki Y, et al. Comparative study of blood group-recognizing lectins toward ABO blood group antigens on neoglycoproteins, glycopro-

- teins and complex-type oligosaccharides. *Biochim Biophys Acta* 2001; 1525: 50–57.
63. van Schooten CJ, Denis CV, Lisman T, et al. Variations in glycosylation of von Willebrand factor with O-linked sialylated T-antigen are associated with its plasma levels. *Blood* 2006; 109: 2430–2437.
64. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. *J Clin Invest* 1991; 88: 774–782.
65. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. *Blood* 1996; 87: 4223–4234.
66. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. *Blood* 1996; 87: 4235–4244.
67. Bowen DJ. Genome-wide linkage analysis of von Willebrand factor plasma levels implicates the ABO locus as a principal determinant: should we overlook ADAMTS13? *Thromb Haemost* 2003; 90: 961.
68. Millar CM, Starke R, Riddel AF, et al. Investigation of relationship between ADAMTS-13, von Willebrand factor antigen and collagen-binding activity in patients with type 1 von Willebrand disease. *J Thromb Haemost* 2005; 3 (Suppl 1): P1471.
69. Lenting PJ, van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. *J Thromb Haemost* 2007; 5: 1353–1360.
70. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. *J Biol Chem* 2004; 279: 12102–12109.
71. van Schooten CJ, Denis CV, Oortwijn BD, et al. Liver and spleen macrophages contribute to the clearance of von Willebrand factor and its complex with factor VIII. *J Thromb Haemost* 2007; 5 (Suppl 1): O-W-017.
72. Schneider SW, Nuschele S, Wixforth A, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. *Proc Natl Acad Sci USA* 2007; 104: 7899–7903.
73. Murphy JE, Pan C, Barnett T, et al. Site-specific pegylation of rFVIII results in prolonged in vivo efficacy. *J Thromb Haemost* 2007; 5 (Suppl 1): P-T-022.
74. Regan L, Jiang X, Ramsey P, et al. Biological activity of pegylated factor VIII. *J Thromb Haemost* 2007; 5 (Suppl 1): P-T-026.
75. Noe DA. A mathematical model of coagulation factor VIII kinetics. *Haemostasis* 1996; 26: 289–303.
76. Schambeck CM, Grossmann R, Zonnur S, et al. High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII. *Thromb Haemost* 2004; 92: 42–46.
77. Lollar P, Parker CG. Stoichiometry of the porcine factor VIII-von Willebrand factor association. *J Biol Chem* 1987; 262: 17572–17576.
78. Leyte A, Verbeet MP, Brodniewicz-Proba T, et al. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII. *Biochem J* 1989; 257: 679–683.
79. Turecek PL, Scheiflinger F, Siekmann J, et al. Biochemical and functional characterization of chemically modified recombinant von Willebrand factor (rVWF) as a carrier prolonging survival of rFVIII in hemophilia A knock-out mice. *J Thromb Haemost* 2007; 5 (Suppl 1): O-M-018.
80. Turecek PL, Siekmann J, Weber A, et al. Modification of rVWF with polysialic acid: Biochemical and functional characterization in mice with VWD. *ASH Annual Meeting Abstracts* 2006; 108: 1001.
81. Hermeling S, Crommelin DJ, Schellekens H, et al. Structure-immunogenicity relationships of therapeutic proteins. *Pharm Res* 2004; 21: 897–903.
82. Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. *Pharmacotherapy* 2003; 23: 3S-8S.
83. Tang L, Pan C, Atwal H, et al. Pegylation protects factor VIII from the inhibition of antibody inhibitors. *J Thromb Haemost* 2007; 5 (Suppl 1): P-T-036.
84. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. *Blood* 2002; 100: 3457–3469.
85. van Dijk K, van der Bom JG, Lenting PJ, et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. *Haematologica* 2005; 90: 494–498.